WO2016126026A3 - 당뇨병 치료 조성물 및 이의 용도 - Google Patents

당뇨병 치료 조성물 및 이의 용도 Download PDF

Info

Publication number
WO2016126026A3
WO2016126026A3 PCT/KR2016/000628 KR2016000628W WO2016126026A3 WO 2016126026 A3 WO2016126026 A3 WO 2016126026A3 KR 2016000628 W KR2016000628 W KR 2016000628W WO 2016126026 A3 WO2016126026 A3 WO 2016126026A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating diabetes
composition
present
diabetes
insulin
Prior art date
Application number
PCT/KR2016/000628
Other languages
English (en)
French (fr)
Other versions
WO2016126026A2 (ko
Inventor
정혜승
박경수
Original Assignee
서울대학교병원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교병원 filed Critical 서울대학교병원
Publication of WO2016126026A2 publication Critical patent/WO2016126026A2/ko
Publication of WO2016126026A3 publication Critical patent/WO2016126026A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 저농도의 PERK(Eukaryotic translation initiation factor 2-alpha kinase 3) 저해제를 유효성분으로 함유하는, 당뇨병 치료용 약학적 조성물 및 이의 용도에 관한 것이다. 본 발명에 의하면, 고혈당 자극에 의한 췌장 베타세포 내 칼슘 및 인슐린을 증가시킴으로써 혈중 인슐린 농도를 높이고, 당뇨병을 치료할 수 있다.
PCT/KR2016/000628 2015-02-04 2016-01-21 당뇨병 치료 조성물 및 이의 용도 WO2016126026A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150017614 2015-02-04
KR10-2015-0017614 2015-02-04
KR10-2015-0164414 2015-11-24
KR20150164414 2015-11-24

Publications (2)

Publication Number Publication Date
WO2016126026A2 WO2016126026A2 (ko) 2016-08-11
WO2016126026A3 true WO2016126026A3 (ko) 2016-09-29

Family

ID=56564848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/000628 WO2016126026A2 (ko) 2015-02-04 2016-01-21 당뇨병 치료 조성물 및 이의 용도

Country Status (1)

Country Link
WO (1) WO2016126026A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190388426A1 (en) 2017-01-30 2019-12-26 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534815A (ja) * 2000-06-08 2003-11-25 デフヘン・ナムローゼ・フェンノートシャップ インスリン欠乏又はインスリン抵抗性に関する化合物スクリーン
KR20110039326A (ko) * 2008-07-08 2011-04-15 인텔리카인, 인크. 키나제 억제제 및 사용 방법
KR20130018272A (ko) * 2010-03-25 2013-02-20 글락소스미스클라인 엘엘씨 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534815A (ja) * 2000-06-08 2003-11-25 デフヘン・ナムローゼ・フェンノートシャップ インスリン欠乏又はインスリン抵抗性に関する化合物スクリーン
KR20110039326A (ko) * 2008-07-08 2011-04-15 인텔리카인, 인크. 키나제 억제제 및 사용 방법
KR20130018272A (ko) * 2010-03-25 2013-02-20 글락소스미스클라인 엘엘씨 화합물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATKINS, C. ET AL.: "Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity", CANCER RESEARCH, vol. 73, no. 6, 15 March 2013 (2013-03-15), pages 1993 - 2002, XP055316275 *
AXTEN, J. M. ET AL.: "Discovery of 7-Methyl-5-(1-{[3-(Trifluoromethyl) Phenyl]Acetyl}-2, 3-Dihydro-1 H-Indol-5-Yl)-7 H-Pyrrolo [2, 3-d] Pyrimidin-4-Amine (GSK2606414), a Potent and Selective First-in-class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 16, 2012, pages 7193 - 7207, XP055189030 *

Also Published As

Publication number Publication date
WO2016126026A2 (ko) 2016-08-11

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
PH12018500690A1 (en) Novel insulin analogs and use thereof
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
PH12019502655A1 (en) Acylated insulin compound
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
WO2018097570A3 (ko) 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
WO2016190566A3 (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
WO2016126026A3 (ko) 당뇨병 치료 조성물 및 이의 용도
MD4763C1 (ro) Compoziţie farmaceutică
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
WO2020018058A3 (en) The injectable micronized human insulin
UA118492C2 (uk) 3,2-бензотіазепін-3,3-діоксиди та спосіб їх отримання
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
UA118493C2 (uk) Конденсовані 1,2,4-тіадіазепіни та спосіб їх отримання
UA99891C2 (ru) Производные метил-3-(3-r-6-r-имидазо[1,2-а]пиридин-2-ил)акрилата и способ их получения
NZ724595A (en) Glucokinase activator compositions for the treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16746767

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 11.10.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 16746767

Country of ref document: EP

Kind code of ref document: A2